Table 5.

Changes in metabolic parameters in the studies that used SGLT2 inhibitors in women with PCOS.

	Cai et al. [31]	Elkind-Hirsch et al. [32]	Javed et al. [33]	Zhang et al. [35]
SGLT2 inhibitor	Canagliflozin	Dapagliflozin	Empagliflozin	Canagliflozin (with Metformin)
Total Cholesterol
Pretreatment	4.87 mmol/L (4.58 to 5.16)	183 mg/dL ± 6	4.8 mmol/L ± 1.0	4.90 mmol/L ± 0.93
Posttreatment	LS mean: 0.17 mmol/L (−0.05 to 0.39)	186 mg/dL ± 11 (+3.0)	4.7 mmol/L ± 1.1	4.54 mmol/L ± 0.80 *
Triglycerides
Pretreatment	1.75 mmol/L (1.37 to 2.14)	143 mg/dL ± 21	1.5 mmol/L (1.3)	1.54 mmol/L (1.09–2.01)
Posttreatment	LS mean: −0.36 mmol/L (−0.54 to −0.17)	n/a	1.4 mmol/L (0.9)	1.20 mmol/L (0.84–1.63) *
LDL
Pretreatment	3.04 mmol/L (2.66 to 3.43)	107 mg/dL ± 6	2.8 mmol/L ± 1.0	3.06 mmol/L ± 0.97
Posttreatment	LS mean: 0.22 mmol/L (0.06 to 0.51)	113.5 mg/dL ± 10 (6.5)	2.7 mmol/L ± 1.1	2.83 mmol/L ± 0.70
HDL
Pretreatment	1.33 mmol/L (1.12 to 1.54)	44 mg/dL ± 2	1.1 mmol/L ± 0.2	-
Posttreatment	LS mean: 0.02 mmol/L (−0.17 to 0.13)	43 mg/dL ± 2.2 (−1.0)	1.1 mmol/L ± 0.2	-

* p < 0.05; [31]. To convert from mg/dL to mmol/L divide mg/dL by 18.